Experimental cell therapy targets deadly childhood brain cancer
NCT ID NCT03396575
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested a new immunotherapy approach for children with DIPG, a rare and aggressive brain stem tumor. After standard radiation and chemotherapy, patients received special vaccines and immune cells designed to attack the tumor. The study was small (11 participants) and was terminated early, so it is unclear how well it works, but researchers were checking for safety and immune responses.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- TTRNA-DC vaccines with GM-CSF and TTRNA-xALT T cells
- What this could lead to
- If it works, this could point toward a new treatment approach for DIPG, a rare and deadly childhood brain cancer.
- What could go wrong
- This was a very early, small Phase I trial that was terminated early, so results are limited. The treatment involves strong chemotherapy and cell therapy, which can cause serious side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRAIN STEM GLIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UF Health Shands Children's Hospital
Gainesville, Florida, 32610, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.